Application of thioredoxin reductase in monitoring the curative effect of lung cancer

doi:10.3969/j.issn.1673-8640.2022.01.011

Abstract

Abstract:

Objective To investigate the role of plasma thioredoxin reductase（TR） in monitoring the efficacy of chemotherapy in lung cancer. Methods Totally,482 lung cancer patients were classified into 2 groups according to the efficacy of chemotherapy,which were unbenefited group（211 cases） and benefited group（271 cases）. TR,carcinoembryonic antigen（CEA）,squamous cell carcinoma antigen（SCC-Ag）,cytokeratin 19 fragment（CYFRA 21-1）,neuron-specific enolase（NSE） and gastrin-releasing peptide precursor（ProGRP） levels were determined. Receiver operating characteristic（ROC） curve was used to evaluate the roles of single and combined determinations of each indicator in judging the efficacy of chemotherapy. Results TR,CEA and NSE levels in unbenefited group were higher than those in benefited group（P<0.05）,and there was no statistical significance in SCC-Ag,CYFRA 21-1 and ProGRP levels between the 2 groups（P>0.05）. The positive rate of TR in unbenefited group was 56.40%,which was higher than that in benefited group（13.16%）（P<0.05）. ROC curve analysis showed that the areas under curves（AUC） of TR,CEA,CYFRA 21-1,SCC-Ag,NSE and ProGRP single determinations to judge the efficacy of chemotherapy were 0.759,0.667,0.579,0.530,0.619 and 0.544,respectively. The AUC of combined determinations of TR+CEA,TR+CEA+CYFRA 21-1,TR+CEA+CYFRA 21-1+NSE and TR+CEA+CYFRA 21-1+NSE+ProGRP were 0.757,0.749,0.752 and 0.788,respectively. TR did not correlate with CEA,NSE,SCC-Ag,CYFRA 21-1 and ProGRP（r=0.05,0.02,-0.15,0.05 and 0.10,P>0.05）. Conclusions TR may serve as a biomarker for monitoring lung cancer curative effect.

Key words: Thioredoxin reductase, Tumor marker, Lung cancer, Chemotherapy, Curative effect evaluation

CLC Number:

Q554

MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer[J]. Laboratory Medicine, 2022, 37(1): 56-59.

Figures/Tables 3

References 12

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI URL
[2]	MAO Y, YANG D, HE J, et al. Epidemiology of lung cancer[J]. Surg Oncol Clin N Am, 2016, 25(3):439-445. DOI URL
[3]	KIM E S. Chemotherapy resistance in lung cancer[J]. Adv Exp Med Biol, 2016, 893:189-209.
[4]	端木忠, 游奕琳, 白曼, 等. 硫氧还蛋白还原酶:一种新型有效的胃癌化疗疗效监测标志物[J]. 中国生物化学与分子生物学报, 2019, 35(12):1367-1374.
[5]	YE S, CHEN X, YAO Y, et al. Thioredoxin reductase as a novel and efficient plasma biomarker for the detection of non-small cell lung cancer:a large-scale,multicenter study[J]. Sci Rep, 2019, 9(1):2652. DOI URL
[6]	PENG W, ZHOU Z, ZHONG Y, et al. Plasma activity of thioredoxin reductase as a novel biomarker in gastric cancer[J]. Sci Rep, 2019, 9(1):19084. DOI URL
[7]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. DOI URL
[8]	陈伟, 李明明, 姚厚山, 等. 肿瘤标志物和炎性指标对结直肠癌诊断和化疗不良反应预测的临床价值[J]. 肿瘤, 2018, 38(11):1038-1047.
[9]	HAO C, ZHANG G, ZHANG L. Serum CEA levels in 49 different types of cancer and noncancer diseases[J]. Prog Mol Biol Transl Sci, 2019, 162:213-227.
[10]	GUO N N, SUN X J, XIE Y K, et al. Cloning and functional characterization of thioredoxin gene from kuruma shrimp Marsupenaeus japonicus[J]. Fish Shellfish Immunol, 2019, 86:429-435. DOI URL
[11]	CADENAS C, FRANCKENSTEIN D, SCHMIDT M, et al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer[J]. Breast Cancer Res, 2010, 12(3):R44. DOI URL
[12]	WU X, WANG Q, LU Y, et al. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer[J]. Sci Rep, 2021, 11(1):6069. DOI URL

组别	例数	TR		CEA		CYFRA 21-1
组别	例数	检测值/（U/mL）	阳性率/%	检测值/（ng/mL）	阳性率/%	检测值/（ng/mL）	阳性率/%
治疗获益组	271	6.44（5.22~7.45）	13.65	7.08（2.78~25.89）	62.30	4.53（2.29~10.27）	54.63
治疗未获益组	211	8.62（6.60~10.50）	56.40	17.66（6.51~243.03）	85.14	5.89（3.01~11.97）	67.07
统计值		-9.760	477.946	-4.228	191.768	-1.868	2.773
P值		0.000 0	0.000 0	0.000 0	0.001 0	0.061 7	0.099 0
组别		SCC-Ag		NSE		ProGRP
组别		检测值/（ng/mL）	阳性率/%	检测值/（ng/mL）	阳性率/%	检测值/（pg/mL）	阳性率/%
治疗获益组		1.90（1.20~3.10）	16.67	17.25（13.00~24.92）	58.95	69.63（50.49~99.19）	75.76
治疗未获益组		5.89（3.01~11.97）	15.12	20.74（15.36~39.73）	75.68	78.37（49.84~225.93）	74.14
统计值		-0.591	1.134	-2.418	5.320	-1.162	1.577
P值		0.556 2	0.833 0	0.010 4	0.022 0	0.264 4	0.851 0

组别	例数	TR		CEA		CYFRA 21-1
组别	例数	检测值/（U/mL）	阳性率/%	检测值/（ng/mL）	阳性率/%	检测值/（ng/mL）	阳性率/%
治疗获益组	271	6.44（5.22~7.45）	13.65	7.08（2.78~25.89）	62.30	4.53（2.29~10.27）	54.63
治疗未获益组	211	8.62（6.60~10.50）	56.40	17.66（6.51~243.03）	85.14	5.89（3.01~11.97）	67.07
统计值		-9.760	477.946	-4.228	191.768	-1.868	2.773
P值		0.000 0	0.000 0	0.000 0	0.001 0	0.061 7	0.099 0
组别		SCC-Ag		NSE		ProGRP
组别		检测值/（ng/mL）	阳性率/%	检测值/（ng/mL）	阳性率/%	检测值/（pg/mL）	阳性率/%
治疗获益组		1.90（1.20~3.10）	16.67	17.25（13.00~24.92）	58.95	69.63（50.49~99.19）	75.76
治疗未获益组		5.89（3.01~11.97）	15.12	20.74（15.36~39.73）	75.68	78.37（49.84~225.93）	74.14
统计值		-0.591	1.134	-2.418	5.320	-1.162	1.577
P值		0.556 2	0.833 0	0.010 4	0.022 0	0.264 4	0.851 0

项目	AUC（95%可信区间）	最佳临界值	敏感性/%	特异性/%	Youden指数
TR	0.759（0.718~0.796）	8.01 U/mL	56.40	87.45	0.439
CEA	0.667（0.597~0.733）	35.29 ng/mL	44.59	83.61	0.282
CYFRA 21-1	0.579（0.506~0.650）	4.9 ng/mL	58.54	55.56	0.141
SCC-Ag	0.530（0.444~0.615）	0.7 ng/mL	14.81	93.02	0.078
NSE	0.619（0.541~0.693）	15.36 ng/mL	74.32	46.32	0.206
ProGRP	0.544（0.463~0.624）	233.3 ng/mL	20.69	93.94	0.146
TR+CEA	0.757（0.690~0.815）		50.00	93.93	0.434
TR+CEA+CYFRA 21-1	0.749（0.660~0.825）		73.13	68.75	0.419
TR+CEA+CYFRA 21-1+NSE	0.752（0.651~0.836）		68.97	76.47	0.454
CEA+CYFRA 21-1+NSE+ProGRP	0.622（0.501~0.733）		33.33	100.00	0.333
TR+CEA+CYFRA 21-1+NSE+ProGRP	0.788（0.676~0.876）		57.78	96.30	0.541

项目	AUC（95%可信区间）	最佳临界值	敏感性/%	特异性/%	Youden指数
TR	0.759（0.718~0.796）	8.01 U/mL	56.40	87.45	0.439
CEA	0.667（0.597~0.733）	35.29 ng/mL	44.59	83.61	0.282
CYFRA 21-1	0.579（0.506~0.650）	4.9 ng/mL	58.54	55.56	0.141
SCC-Ag	0.530（0.444~0.615）	0.7 ng/mL	14.81	93.02	0.078
NSE	0.619（0.541~0.693）	15.36 ng/mL	74.32	46.32	0.206
ProGRP	0.544（0.463~0.624）	233.3 ng/mL	20.69	93.94	0.146
TR+CEA	0.757（0.690~0.815）		50.00	93.93	0.434
TR+CEA+CYFRA 21-1	0.749（0.660~0.825）		73.13	68.75	0.419
TR+CEA+CYFRA 21-1+NSE	0.752（0.651~0.836）		68.97	76.47	0.454
CEA+CYFRA 21-1+NSE+ProGRP	0.622（0.501~0.733）		33.33	100.00	0.333
TR+CEA+CYFRA 21-1+NSE+ProGRP	0.788（0.676~0.876）		57.78	96.30	0.541

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639.
[3]	YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341.
[4]	YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346.
[5]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[6]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[7]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[8]	WEN Jing, SHI Rui, XIE Jia, LIU Feng, LI Guang, REN Jingjing, LEI Xiaoru, GUO Xiaobo, SONG Yanping. Clinical application of metagenomic next-generation sequencing for determining pathogens in febrile neutropenic patients [J]. Laboratory Medicine, 2022, 37(9): 855-859.
[9]	LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR⁺-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740.
[10]	LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422.
[11]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.
[12]	ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355.
[13]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[14]	XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163.
[15]	XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55.